Virtual Symposium: Antithrombotic Therapy for Symptomatic PAD: Interpreting the Evidence and Recent Advances

Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.

Furthermore, peripheral revascularization has become increasingly common in PAD patients, however, patients who undergo this procedure are still at an increased risk for future adverse events, particularly for acute limb ischemia. Given these heightened risks in PAD patients with cardiometabolic disease or risk, traditional antiplatelet strategies may not be adequate. Several clinical trials have been recently concluded or ongoing that have evaluated novel antithrombotic therapy in this setting, and these advances and their clinical practice implications will be covered during this symposium by expert faculty.

This activity is part of the PAD Digital Highlights Hub.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, registered nurses, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiology and major complications of peripheral artery disease and the heightened risk in cardiometabolic patients.
  • Summarize the major findings and implications of trials evaluating the role of direct oral anticoagulants in the management of high-risk patients with stable PAD.
  • Discuss recent data about the role of direct oral anticoagulants in patients with PAD who have undergone lower-extremity revascularization.
  • Develop individualized strategies for the prevention of adverse cardiovascular and limb events in high-risk cardiometabolic patients with PAD.
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Course opens: 
Course expires: 


Deepak L. Bhatt, MD (Chair)
Professor of Medicine
Harvard Medical School
Executive Director
Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Boston, MA

Dr. Bhatt discloses the following:
Contracted Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, MyoKardia, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company



Marc P. Bonaca, MD
Director of Vascular Research
Associate Professor of Medicine
University of Colorado School of Medicine
Aurora, CO

Dr. Bonaca discloses the following:
Consulting Fees: Amgen, Astrazeneca, Bayer, Janssen, Sanofi, Merck NovoNordisk
Contracted Research: Grant Support to CPC from: Amgen, Astrazeneca, Bayer, Janssen, Lexicon,(Sanofi), NovoNordisk; grant support to BWH from Pfizer



Manesh R. Patel, MD
Richard S. Stack Distinguished Professor
Chief, Division of Cardiology
Co-Director Duke Heart Center
Duke Clinical Research Institute
Duke University
Durham, NC

Dr. Patel discloses the following:
Consulting Fees: Bayer, Janssen, Amgen
Contracted Research: Bayer, Janssen, Amgen, NHLBI


1.0 hour

This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.

image   image   image

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-21-2856-H01-P.

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 1.0 CPEUs for dieticians.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period June 29, 2021 through June 29, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.